CEACAM1 and cancer: It is proposed that by allowing urological surgeons access to laboratory markers such as HER-2, Thrombomodulin, CEACAM-1 and CD31, potentially, in the future, these biomarkers may be used in addition to, or in combination with, currently used scoring systems to predict cancer recurrence and progression.